| 包装 | 价格(元) |
| 500 µg | 电议 |
| 1mg | 电议 |
| 别名 | Oxaprozinum-d5; Wy21743-d5 |
| Canonical SMILES | OC(CCC1=NC(C2=CC=CC=C2)=C(C3=C([2H])C([2H])=C([2H])C([2H])=C3[2H])O1)=O |
| 分子式 | C18H10D5NO3 |
| 分子量 | 298.4 |
| 溶解度 | DMF: soluble,DMSO: soluble,Ethanol: soluble,Methanol: soluble |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Oxaprozin-d5is intended for use as an internal standard for the quantification of oxaprozin by GC- or LC-MS. Oxaprozin is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 2.2 and 36 μM for human COX-1 and COX-2, respectively).1It decreases acetic acid-induced writhing times and carrageenan-induced paw edema in mice when administered at doses of 100 and 70 mg/kg, respectively.2Formulations containing oxaprozin have been used in the treatment of pain associated with osteoarthritis and rheumatoid arthritis. 1.Kawai, S., Nishida, S., Kato, M., et al.Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cellsEur. J. Pharmacol.347(1)87-94(1998) 2.Zhou, X.P., Zhang, M.X., Sun, W., et al.Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drugBiol. Pharm. Bull.32(12)1986-1990(2009) |
m.cnreagent.com